Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium (186Re) obisbemeda
- Development stage
- Unknown
- Lead developer
- Cerenome
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Intrathecal
01
Overview
Rhenium (186Re) obisbemeda (brand name REYOBIQ, also known as 186RNL or by its clinical trial name ReSPECT) is a radiopharmaceutical developed by Plus Therapeutics (marketed under the Cerenome brand) for the treatment of central nervous system (CNS) malignancies. It consists of a nanoliposome carrier that encapsulates Rhenium-186, a radioisotope that emits both beta particles for localized tissue destruction and gamma rays for real-time imaging and dosimetry. The drug is administered locoregionally via convection-enhanced delivery (CED) for solid tumors like recurrent glioblastoma or via intraventricular injection for leptomeningeal metastases. This targeted approach allows for the delivery of radiation doses significantly higher than those achievable with external beam radiation while minimizing systemic exposure and toxicity.
- Brand names
- REYOBIQReSPECT
- Other names
- Rhenium-186 NanoLiposomeRhenium186 NanoLiposomeRhenium 186 NanoLiposome186Re-Liposomerhenium-186 obisbemedarhenium186 obisbemedarhenium 186 obisbemeda
02
Targets
DNA
Beyond the preview
Go deeper on rhenium (186Re) obisbemeda.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium (186Re) obisbemeda.